Tawanda Gumbo, M.D., was born in Zimbabwe, and attended the University of Zimbabwe Medical School. From 1993 to 1996 he was an intern and resident in Internal Medicine/International Health Tract at Case Western Reserve University at MetroHealth Medical Center in Cleveland, Ohio, and from 1996-1999 he was a fellow in Infectious Diseases at the Cleveland Clinic Foundation in Cleveland, Ohio.
In 2001 he joined the Albany Medical College and the Ordway Research Institute in Albany, New York, where he worked on establishing the mouse model of disseminated Candida glabrata and the hollow fiber model of tuberculosis in 2002. He was the inaugural Director of Transplant Infectious Diseases for the newly established transplant surgery program, and the Infectious Diseases member of Center for Donation and Transplant (CDT), a UNOS organ procurement organization for New York, Vermont, and Western Massachusetts.
In 2006 he moved to UT Southwestern Medical Center. The Gumbo Laboratory has elucidated the role of efflux pumps in survival of Mycobacterium tuberculosis and examined molecules that could exploit these to enhance antituberculosis therapy. Work has also included integrating pharmacogenomics into clinical trial simulations for antituberculosis drugs with multimodal systemic elimination, establishment of a mathematical model for the relationship between antimicrobial drug exposure and resistance emergence, the establishment of new susceptibility breakpoints of first-line antituberculosis drugs, and recently a series of hollow fiber model of tuberculosis and computer-aided clinical trial simulations as well as clinical data that have questioned the role of adherence in therapy failure and proposed the pharmacokinetic variability hypothesis for therapy failure and acquired drug resistance. These findings were then confirmed in a series of clinical studies conducted jointly with research partners at the University of Cape Town.
In 2007 he received the NIH Director’s New Innovator Award to focus on efflux pump inhibition to accelerate therapy and reduce duration of antituberculosis therapy. In 2009 he was a Mellon Visiting Scholar at the University of Cape Town in South Africa. In 2013 the hollow fiber model of tuberculosis was presented before the FDA, and in 2014 presented to the European Medicines Agency for qualification as a drug development tool by CPTR.
He is a contributor for two chapters in the 12th edition of the pre-eminent pharmacology text "Goodman and Gilman’s The Pharmacological Basis of Therapeutics" namely, "Principles of Chemotherapy of Infectious Diseases" and "Chemotherapy of Tuberculosis, Mycobacterium avium Complex, Leprosy." Dr. Gumbo has also published a poetry book, "Songs for flame lily" (2005), that is arranged based on courtship stages of traditional Bantu society.
He joined UT Southwestern's Office of Global Health in 2011.
|Medical School||"university of Zimbabwe Med School, Zimbabwe" , Medicine|
|Undergraduate||"university of Zimbabwe Med School, Zimbabwe,afric (1991)|
- Advanced pharmacometrics, antimicrobial pharmacokinetic-pharmacodynamics and pharmacogenetics
- Application of fractal geometry and chaos theory to quantitative and systems pharmacology
- Computer aided clinical trial simulations
- Development of novel efflux pump Inhibitors to enhance antibiotic efficacy
- Individualized Bayesian feedback dose optimization
- Mathematical model development for the relationship between mycobacterial cells and drug concentration
- Systems Pharmacology and mathematical scaling studies for M. tuberculosis, M. avium complex, and M. kansasii
Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R Lancet Respir Med 2014 Apr 2 4 321-338
Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T J. Infect. Dis. 2013 Jul
Gumbo T Nat. Genet. 2013 Jun 45 7 720-1
Pasipanodya JG, Gumbo T Clin. Infect. Dis. 2013 Mar
Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T Antimicrobial agents and chemotherapy 2012 Jul
Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T J. Infect. Dis. 2011 Dec 204 12 1951-9
Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL J. Infect. Dis. 2004 Nov 190 9 1642-51
Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H J. Antimicrob. Chemother. 2014 May
Srivastava S, Gumbo T Eur. Respir. J. 2014 Jan 43 1 312-3
Pusch T, Pasipanodya JG, Hall RG, Gumbo T BMC Infect. Dis. 2014 14 115
General Principles of Chemotherapy of Infectious Diseases. In Goodman & Gilman's The Pharmacological Basis of Therapeutics
Tawanda Gumbo (2010). The McGraw-Hill Companies, Inc
Chemotherapy of Tuberculosis, Mycobacterium avium Complex, Leprosy. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th Edition
Tawanda Gumbo (2010). The McGraw-Hill Companies, Inc
Application of pharmacogenomics in therapeutics: Infectious Diseases. In Concepts in Pharmacogenomics
Tawanda Gumbo & John D. Cleary (2010). Bethesda, MD, American Society of Health-System Pharmacists
Tuberculosis and other Mycobacterial Diseases. In Conn's Current Therapy
Jotam Pasipanodya, Ronald Hall II, Tawanda Gumbo (2010, 2011, 2012, 2013, 2014). Philadelphia, Elsevier, Saunders
Glucan Synthase Inhibitors. In Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 2nd Ed
Tawanda Gumbo, Fumiaki Ikeda, Arnold Louie (2007). New York, NY, Informa Healthcare
Honors & Awards
- Mellon Visiting Scholar
University of Cape Town (2009)
- NIH Director’s New Pioneer Innovator Award
National Institutes of Health (2007)
- Certificate of Distinction
Australian Mathematics Competition for the Westpac Awards, Senior Division (1986)
- American Association for the Advancement of Science
- American Society for Microbiology
- Infectious Diseases Society of America
- International Society of Anti-Infective Pharmacology